Myeloma

For example, a large iliac or sacral plasmacytoma causing symptoms. Both medical oncologists and radiation oncologists get nervous about RT-related cy...

1 Answer available

How often do you assess for frailty in your clinical practice for patients with Multiple Myeloma and what tool do you use?

For example: eyeball test, simplified frailty assessment (Facon et al.), IMWG frailty score, ECOG only?

1 Answer available

How do you approach treatment for patients with proliferative glomerulonephritis with monoclonal IgG deposits (PGNMID) with end-stage renal disease who are considering kidney transplant?

Most patients with PGNMID have no detectable disease in their marrow or blood and urine protein cannot adequately be monitored.

1 Answer available

Does the degree of elevation in free light chains/ratio correlate with a probability of AL amyloidosis?

Does a certain level of free light chain ratio reassure you against the possibility of AL amyloid? Is there a certain level that makes you more concer...

1 Answer available

What is your preferred approach to a patient with myeloma who has refractory disease to Dara-VRd in the frontline setting?

2 Answers available

How are you dosing IVIG following BCMA CAR-T or bispecific antibodies in multiple myeloma?

Do you only offer it for patients with a documented IgG < 400? Do you check the IgG at all, or are you doing primary prophylaxis?

1 Answer available

How do you approach initial treatment for AL amyloidosis with excess plasmacytosis in the bone marrow, that has cardiac involvement and is not a transplant candidate?

Let's assume they have cardiac involvement and transplant may not be feasible.

1 Answer available

How would you approach dose modifications and/or frequency of lenalidomide in patients with advanced renal impairment (eGFR <30)?

The FDA package insert suggests 2.5 mg daily in these settings, while the PrE1003 study demonstrated that a higher dose is feasible. Many oncologists ...

2 Answers available

What is your approach to determining fitness for patients to undergo CAR-T therapy for relapsed/refractory multiple myeloma, and any absolute perceived contraindications for CAR-T?

1 Answer available

In what scenarios (if ever) would you check peripheral blood flow cytometry in a patient with known multiple myeloma to evaluate for circulating plasma cells (CPCs) in the absence of an abnormal smear?

There are some retrospective data that CPCs are associated with worsened outcomes after transplantation. Anecdotally, CPCs could be collected as part ...

1 Answer available

How do you monitor multiple myeloma in patients receiving dialysis?

Since free light chains are removed by dialysis and SPEP can also be impacted, is there a reliable way to monitor patients with ESRD and MM?

1 Answer available

How do you modify Daratumumab-RVD relative to the protocols used in trials when used as a first-line agent to transplant-eligible patients with myeloma?

E.g. frequency of Bortezomib, dosing of Bortezomib, length of cycles.

1 Answer available

Based on the DREAMM-7 and DREAMM-8 data, if approved again in the US, how would you incorporate belantamab mafadotin in your practice?

2 Answers available

Based on the IMROZ and BENEFIT data, would you recommend quadruplet therapy for non transplant eligible newly diagnosed multiple myeloma?

1 Answer available

With the recent approvals of CAR-T for second-line therapy in myeloma, does this change your approach to use of consolidative autologous transplant or autologous transplant as second line therapy?

2 Answers available

In 2024, do you consider isolated gain(1q) [not amp(1q)] to be a high-risk cytogenetic abnormality in multiple myeloma?

Most would argue that gain(1q) in combination with another high-risk feature constitutes ultra-high-risk multiple myeloma, and most would argue (with ...

1 Answer available

What is your threshold to diagnose light chain MGUS with only a slight elevation in the light chain ratio, in a patient without other CRAB symptoms and no M spike?

When would you consider a bone marrow biopsy?

4 Answers available

How long should we treat patients with newly diagnosed myeloma with bisphosphonates or RANKL inhibitors for their myeloma bone disease given recent data?

The OS benefit with Zometa was seen only in patients with myeloma bone disease achieving less than or equal to a partial response. SRE risk reduction ...

1 Answer available

Is there any value to getting a bone marrow biopsy at the time of biochemical relapse in multiple myeloma before switching to a new line of therapy?

For many clinical trials, a screening bone marrow biopsy is necessary to get a new baseline. Do you do the same in real-world practice?

3 Answers available

Do you resume zoledronic acid or denosumab at relapse in multiple myeloma?

Previous questions have focused on the newly diagnosed setting and choice of bisphosphonate versus denosumab. IMWG guidelines do recommend resuming zo...

2 Answers available

In the current myeloma landscape, do you make treatment decisions based on MRD results, either for MRD negativity or MRD resurgence?

2 Answers available

How do you utilize immunoglobulin testing to affect treatment decisions in patients with myeloma?

What does it add beyond a serum electrophoresis or light chain testing? Are there certain types of patients where monitoring immunoglobulins is parti...

1 Answer available

For patients on commercial teclistamab who achieve a response, are there patient-specific or response-specific parameters that would prompt you to de-escalate therapy from once per week?

For example - minimum number of months of therapy, driving distance to clinic, at least a CR with or without MRD negativity?

3 Answers available

How do you discuss harms of MGUS screening with other medical providers?

For example, how do you address tendency to "over-order" these tests in patients with common aches/pains but no structural abnormalities on advanced i...

2 Answers available

For a Jehovah's Witness patient with multiple myeloma, could you safely offer a BCMA-directed bispecific antibody or CAR-T therapy?

Please assume that IVIG is fine (as it is for many Jehovah's Witness patients, since IgG is often not considered a blood product per se).

2 Answers available

What induction regimen do you choose for high risk newly diagnosed multiple myeloma in light of the recent high risk focused studies?

4 Answers available

Are there any circumstances where you recommend early institution of systemic therapy for patients with solitary plasmacytoma?

Specifically, do you offer closer follow-up for certain patients after local radiation?

3 Answers available

For otherwise transplant-eligible patients with myeloma, given developments of bispecifics and CAR-T, what is your age cutoff for consolidative autologous transplant?

Would you transplant a patient over the age of 70 with newly diagnosed myeloma? Does the risk category impact your decision?

2 Answers available

What is your approach to vaccinations and titers for patients with myeloma, who are immunosuppressed and do not have appropriate antibody responses to vaccines?

E.g., for a patient with myeloma, s/p induction therapy, and high-dose chemotherapy, followed by autologous rescue with inappropriate antibody respons...

3 Answers available

Would you recommend radiation to a painful rib fracture in a patient with multiple myeloma on systemic therapy with ongoing response to treatment?

Is there benefit to radiation on top of systemic therapy?

5 Answers available

How do you approach the initial dosing of carfilzomib for patients with relapsed multiple myeloma?

Is the therapeutic purpose of the proteasome inhibitor to maximize total dosage per week or number of infusions per week?

2 Answers available

How extensive of a workup do you do for systemic AL amyloidosis for a patient with a resected amyloidoma, localized AL amyloid deposition in their airway or lungs, who has no other symptoms?

Would you do a 24-hour urine and echocardiogram in all of these patients? Cardiac biomarkers, PT/PTT, or any other such blood tests?

3 Answers available

How would you approach the treatment of an elderly patient with multiple myeloma and CALR+ myelofibrosis with elevated platelets?

Presuming the patient is not a transplant candidate due to comorbidities, PS, and age.

1 Answer available

What factors do you look at while deciding between a daratumumab-based quadruplet induction versus standard triplet induction such as VRd for newly diagnosed MM?

2 Answers available

How is monoclonal gammopathy of renal significance (MGRS) different from myeloma kidney?

If there are light chain deposits on the kidney, is that conclusive of MGRS?

1 Answer available

For a patient with triple-class-refractory myeloma and cytopenias who has been collected for CAR-T, would you choose aggressive chemotherapy or a bispecific antibody for bridging?

This question seems quite specific but happens quite often. Multi-drug chemotherapy runs the risk of profound cytopenias and infections, while bispeci...

2 Answers available

With the CANOVA results in mind, would you continue using venetoclax in patients with multiple myeloma with t(11;14)?

1 Answer available

What is your approach to mitigating the infection risk with bispecific antibodies in multiple myeloma?

4 Answers available

How would you manage a patient with new renal failure and mild anemia in the setting of a moderate M-Spike and low kappa/lambda ratio, but with negative PET and bone marrow with <10% plasma cells?

1 Answer available

What is your approach to MRD testing in the frontline treatment of multiple myeloma?

How frequently and what type of testing/sample are you performing MRD assessment? Does your approach differ between transplant-eligible and transplan...

1 Answer available

How do you choose between the different recently approved Bispecifics Antibodies for Relapsed/Refractory Multiple Myeloma?

I.e. dosing regimen frequency, side effect profile, duration of follow up, etc.

3 Answers available

For patients who require aggressive debulking in multiple myeloma, what is your preferred chemotherapy regimen and why?

Modified HyperCVAD? V(R)D-PACE? DCEP? Are there any data to favor one over the other?

2 Answers available

How do you manage IgM related peripheral neuropathy?

Do you utilize rituximab or any other specific management strategies?

2 Answers available

How would you approach BCMA-directed therapy in a patient with myeloma and renal failure on dialysis?

Would you prefer CAR-T or bi-specific or neither? If CAR-T, how do you approach lymphodepletion?

2 Answers available

What are alternative myeloma therapies for patients who are unable to afford lenalidomide or oral cyclophosphamide due to gaps in prescription drug coverage?

Several patients with inability to access oral cyclophosphamide or lenalidomide, have attempted assistance and grants to no avail.

1 Answer available

What post-auto maintenance therapy do you recommend for patients with high-risk multiple myeloma?

Given recent retrospective study showing potential lack of benefit with bortezomib-based maintenance therapy (Bumma et al., PMID 37021929).High-risk a...

1 Answer available

How do you approach post-transplant maintenance for patients with high-risk myeloma?

Which PI and at what dosing intervals? Dexamethasone or not? Emory has now published data with VRd consolidation as well as KPd consolidation, while ...

2 Answers available

What are your top takeaways in Hematologic Malignancies from ASCO 2023?

8 Answers available

Do you recommend routinely getting periodic 24-hour urine monoclonal protein study for patients with active multiple myeloma?

If so, why?

4 Answers available

Would you implement CAR-T therapy earlier in practice if approved in earlier lines for multiple myeloma based on the KarMMa-3 and CARTITUTUDE-4 studies?

3 Answers available

How would you approach a patient with solitary plasmacytoma with an FLC ratio >100, but a negative bone marrow biopsy and negative PET-CT?

2 Answers available

Is a bone marrow biopsy necessary in a patient with a previous tissue diagnosis of plasmacytoma or smoldering multiple myeloma, who now meets criteria for active myeloma?

Assuming there is clear laboratory and/or imaging evidence of disease progression, and assuming FISH data is already available from a prior biopsy, do...

1 Answer available

Do you have any concerns about using checkpoint inhibitors in a patient with myeloma who has a second malignancy?

Patient with stable disease on maintenance therapy with lenalidomide and dexamethasone

2 Answers available

Do you always start treatment for patients who meet diagnostic criteria for multiple myeloma by SLiM criteria alone?

i.e., 60+% bone marrow plasmacytosis, light chain ratio >100, and/or >1 MRI lesion

2 Answers available

What would be your next step in workup for a patient with IgG Kappa Monoclonal protein detected on SPEP and free lambda light chains found in the urine, with chronic diarrhea for 3 years and concern for GI amyloidosis?

1 Answer available

How would you treat a patient with two concurrent plasmacytomas whose bone marrow showed no evidence of multiple myeloma and has no other MM defining features?

Normal CBC, CMP, SPEP, serum light chains, and FISH. Young otherwise fit patient.

3 Answers available

Do you routinely prescribe PPI prophylaxis for myeloma patients who will be on low-dose aspirin and weekly dexamethasone?

1 Answer available

Do you change treatment for confirmed biochemical progression in patients with otherwise secretory MM even if the M-spike is <0.5 g/dL?

3 Answers available

Are there situations where you would start treatment for cardiac amyloid in a patient with amyloid seen on biopsy, but still pending mass spectrometry results?

E.g. in a patient with tenuous cardiac function, would starting treatment several weeks earlier potentially improve outcomes?

1 Answer available

How would you approach grade 2 neurologic toxicity in a patient on daratumumab, dexamethasone, and lenalidomide for relapsed multiple myeloma?

Regimen currently 25 mg lenalidomide D1-21 of D28 day cycles, Daratumumab 16 mg/kg every 2 weeks.

1 Answer available

What is your approach to maintenance therapy post autologous stem cell transplant for patients with concurrent multiple myeloma and AL amyloidosis?

Does your choice of agent differ, or are you more or less likely to offer maintenance than if the patient had multiple myeloma alone?

2 Answers available

Do you check beta 2 microglobulin in patients with MGUS?

Does it assist in prognosis in any way?

1 Answer available

Is there still a role for plasma exchange/PLEX for confirmed or suspected cast nephropathy in multiple myeloma to rapidly reduce light chain burden?

In addition to reversing hypercalcemia, initiating myeloma therapy, etc.

1 Answer available

For a patient with MM progressing on a daratumumab-based regimen, is it preferable to entirely switch drug class or is another monoclonal antibody such as isatuximab an acceptable next step?

5 Answers available

What would you use for a maintenance regimen after high dose chemotherapy and autologous stem cell transplant for a patient with 17p-deleted multiple myeloma?

1 Answer available

Assuming all options for BCMA-directed therapy are available, how would you approach treatment for a patient with 4 prior lines of myeloma-directed therapy who is eligible for a BCMA-directed therapy?

Ide-cel? Cilta-cel? Teclistamab?

1 Answer available

For patients with IgG kappa multiple myeloma receiving an IgG kappa mAb (i.e., daratumumab), how important is it clinically to use an interference assay if they're in a VGPR to see if their M-spike might actually be 0?

For example, would you use a tool like the Hydrashift assay? Would this change your management?

1 Answer available

When you use selinexor for relapsed/refractory myeloma, with what total weekly dose do you practically start?

If tolerated through Cycle #1, how aggressively do you try to titrate the selinexor dose up toward 100mg weekly or 80mg twice-weekly? And does your a...

1 Answer available

Do you offer IVIG to myeloma patients with recurrent infections?

Do you have a certain immunoglobulin level which you would use to determine this?

1 Answer available

What is your approach for using anticoagulation/aspirin in patients with multiple myeloma?

2 Answers available

Would you substitute carfilzomib in place of bortezomib in a transplant-eligible AL amyloidosis patient with baseline amyloid neuropathy and worsening neuropathy on bortezomib despite maximal dose reduction?

2 Answers available

Do you anticipate a paradigm shift in first line treatment of multiple myeloma from RVD to immune therapy with CAR-T/bispecifics?

If so, when do you think this might occur?

2 Answers available

For hypogammaglobulinemia as a complication of successful treatment, do you empirically start prophylaxis with either 400 mg/kg monthly for IVIG or 100 mg/kg weekly for subcutaneous immune globulin?

1 Answer available

What is your preferred up-front treatment for transplant-eligible patients with primary (de novo) plasma cell leukemia?

2 Answers available

What is your approach to pRBC transfusion support for myeloma-related anemia?

How much weight do you give to a hgb/hct threshold versus symptoms?

3 Answers available

What are your takeaways from the GPRC5D-Targeted CAR-T trial (Mailankody et al. NEJM Sept 2022) and any key differences compared to the BCMA directed products?

1 Answer available

How do you approach work-up for a patient suspected for monoclonal gammopathy of renal significance for whom renal biopsy is contraindicated?

E.g. a patient with monoclonal protein with mild light chain ratio elevation. Do we need to get a BM biopsy in all such patients?

2 Answers available

If you treat a patient with high-risk smoldering myeloma on trial and they develop biochemical progression by M-spike, but still no CRAB-SLiM criteria, what would you do next?

In this case, the patient had received daratumumab/lenalidomide/dexamethasone as part of a cooperative group trial. Would you say that the patient had...

1 Answer available

Is there a role for repeat CAR-T with a potentially different product in relapsed and refractory multiple myeloma?

2 Answers available

Do you consider discontinuing maintenance therapy in transplant-ineligible patients with Multiple Myeloma?

Other than in the setting of disease progression or significant treatment-related adverse event?

1 Answer available

Do you recommend IVIg and/or cytoreduction for patients with IgM MGUS with reciprocal depression in IgG and recurrent infections?

Infection is not part of the criteria for starting treatment both in UpToDate and in NCCN guidelines.

1 Answer available

Do you perform a periodic PET CT to screen for extramedullary disease in patients with MM who are in remission?

2 Answers available

Where does Elotuzumab-based combination therapy, specifically EPd, fit in your treatment paradigm for relapsed MM?

Does sequence matter?

1 Answer available

What induction regimen would you choose for a patient with newly diagnosed multiple myeloma with incidental amyloidosis noted on bone marrow biopsy, but with no end-organ damage as a result of amyloid deposition?

Would you consider Dara-CyBorD or a MM triplet/quadruplet such as VRd or Dara-VRd?

4 Answers available

Would you add Daratumumab to upfront treatment of multiple myeloma in a patient with tetraploidy on FISH?

1 Answer available

How do you approach treating a patient with IgM-AL amyloidosis?

Given the rarity of this diagnosis (5-7% of all AL amyloidosis cases), and the prognostic and clinical differences when compared to non IgM-AL am...

3 Answers available

How do you approach treatment for a patient with a biochemical relapse while on maintenance lenalidomide after autologous stem cell transplant for multiple myeloma?

What factors (i.e. timing from transplant, dose, prior therapy) impact your decision?

1 Answer available

What is your preferred first line regimen for myeloma with severe renal impairment, either on or off dialysis?

1 Answer available

In transplant-eligible, fit patients with primary refractory myeloma, what is the optimal timing for stem cell collection?

We know the longer we expose patients to lenalidomide, the harder collection will be. Would you collect now or switch to an alternative regimen to ach...

3 Answers available

How do you now approach treatment sequencing in MM in light of the DETERMINATION trial data?

Do the results change your clinical practice?

2 Answers available

How do you approach the decision to pursue early versus delayed autologous stem cell transplantation in newly diagnosed multiple myeloma?

1 Answer available

For patients with multiple myeloma, when using Lenalidomide or Pomalidomide, how do you approach dose adjustment based on patient tolerance?

1 Answer available

In a patient with multiple myeloma on lenalidomide who develops COVID-19 and is going to receive Paxlovid treatment, would you stop lenalidomide for the duration of Paxlovid treatment?

1 Answer available

At this time, how are you using MRD testing for clinical management of patients with multiple myeloma?

1 Answer available

Would you consider CAR-T therapy without autologous transplant in a patient with multiple myeloma whose best response to induction therapy is a partial response?

1 Answer available

What is your approach to treating newly diagnosed plasma cell leukemia?

1 Answer available

In a patient diagnosed with Multiple Myeloma, is there a role for 24-hour UPEP prior to treatment?

Does measuring serum free-light chains make a 24-hour UPEP unnecessary?

1 Answer available

How would you approach therapy for a patient with smoldering multiple myeloma whose light chain ratio has increased to greater than 100 over several years in the absence of any other myeloma-defining events?

Does a progressing kappa/lambda ratio > 100 at any point in time warrant treatment, or does one wait to treat patients in the setting of a slowly i...

2 Answers available

For a patient with concurrent diagnoses of Hodgkin Lymphoma and Light Chain Myeloma complicated by Myeloma Kidney, how would you approach treatment?

What agents would have sufficient efficacy overlap to treat both?

2 Answers available

What would be your approach to initial treatment of a patient with standard-risk myeloma unwilling to undergo autologous stem cell transplant, if practicing in a resource-limited setting?

1 Answer available

For relapsed/refractory myeloma, how long of a disease-free interval from first autologous transplant do you recommend before considering a second autologous transplant?

1 Answer available

What induction combination(s) would be appropriate for newly diagnosed standard cytogenetic risk multiple myeloma who have a transplanted kidney?

Would you avoid imid's given reported association with transplant rejection?

1 Answer available

For patients with mild CKD, how do you decide between zoledronic acid and denosumab for bone protection in patients with multiple myeloma?

For pts w/ eGFR between 30-60

1 Answer available

What is your experience with using Frailty Index or other geriatric screening in making decisions for elderly patients with multiple myeloma?

Frailty Index per Palumbo et al. PMID 25628469Is it practical to apply in clinics? Have you made decision changes based on it?

2 Answers available

In what clinical scenarios do you utilize venetoclax-based therapy in relapsed/refractory multiple myeloma?

Venetoclax has demonstrated efficacy in patients harboring t(11;14) mutations but is not FDA approved for MM. Can you expand on what situations you ma...

3 Answers available

When would you add daratumumab to a PI/IMiD/dex backbone for first-line treatment of transplant-eligible multiple myeloma?

Are the early results of CASSIOPEIA (Abst 8003) from ASCO 2019 practice changing? What about the GRIFFIN results in 2020?

2 Answers available

For patients with myeloma on an IMiD, how do you decide on the dosages of aspirin or anticoagulants in VTE prophylaxis ?

Do you modify the aspirin dose based off the lenalidomide dose? Do you ever use higher dose aspirin in lieu of an anticoagulant? The NCCN guidelines s...

1 Answer available

How do you approach patients with recurrent grade 3+ neutropenia on IMiD-containing regimens (e.g., VRd or KRd) beyond dose reductions?

For example: shorten IMiD duration each cycle, add scheduled G-CSF, add antibacterial prophylaxis, etc.

1 Answer available

What infectious prophylaxis do you use for patients with newly diagnosed multiple myeloma?

How do you decide how long to continue?

1 Answer available

What is your treatment of choice for triple class refractory multiple myeloma?

CAR-T (any specific preference of product?) vs bispecific antibodies vs any other specific agents not previously utilized?

2 Answers available

How does one interpret persistently positive lambda light chains on serum immunofixation but without measurable serum monoclonal protein and a normal light chains and ratio?

Is a repeatedly abnormal serum immunofixation all it takes for MGUS?

2 Answers available

What options are available for patients with relapsed/refractory AL amyloidosis after Dara-CyBorD, other than clinical trial?

1 Answer available

Which patients with smoldering myeloma do you treat?

2 Answers available

How would one alter therapy in a transplant-ineligible AL amyloidosis with less than a complete response to six cycles of Dara-CyBorD?

Would you continue with daratumumab maintenance per ANDROMEDA or switch regimen?

2 Answers available

How do you approach transplant eligible myeloma patients with a partial or minimal response to treatment with 3-4 cycles of RVD?

After 3-4 cycles of RVD, would you automatically take the patient to transplant if he has achieved at least a partial response, or is there any benefi...

1 Answer available

What is the optimal prophylaxis regimen to use prior to a selinexor based regimen in the treatment of multiple myeloma for nausea and electrolyte abnormalities?

2 Answers available

Would you re-challenge a patient with refractory multiple myeloma with carfilzomib who responded well but developed grade 3 heart failure and subsequently recovered the EF upon holding carfilzomib?

If you do recommend resuming carfilzomib, what dose and frequency would you use?

1 Answer available

How do you approach a patient with an anaplastic plasmacytoma without systemic evidence of disease in the bone marrow?

What about multiple anaplastic plasmacytoma without bone marrow involvement?

2 Answers available

Do you recommend work up for POEMS and/or amyloidosis for IgM monoclonal gammopathies associated with neuropathy?

Can you expand on this by sharing exactly what this routine workup should include? What additional tests outside of evaluating for POEMS and amyloidos...

2 Answers available

For young patients with smoldering multiple myeloma who wish to be treated with lenalidomide, how do you go about harvesting their cells for an autologous transplant?

Insurance won't pay for harvesting if the transplant is not done within a year.

2 Answers available

Does multiple myeloma become more radioresistant post transplant?

2 Answers available

How do you utilize serum viscosity in the clinical management of plasma cell disorders?

1 Answer available

Do you continue bortezomib past 8 cycles for transplant ineligible patients with multiple myeloma on VRd who are tolerating therapy well with no neuropathy?

Would you use MRD status to guide your decision making?

1 Answer available

Would you move to a venetoclax-based regimen for a patient with pentarefractory MM and t(11;14) translocation, previously treated with bortezomib and carfilzomib?

If so, venetoclax/dexamethasone by itself or do you include a PI?

2 Answers available

Do you routinely offer a bisphosphonate or denosumab to multiple myeloma patients without skeletal lesions?

Recommendations in guidelines are discordant (ASCO vs NCCN vs UptoDate).

2 Answers available

How do you counsel patients referred for abnormal light chain ratio when individual light chains are in normal range?

2 Answers available

What is your preferred maintenance strategy for high risk multiple myeloma?

2 Answers available

Should patients with active multiple myeloma and other gammopathies be routinely vaccinated against herpes zoster?

If yes would you delay initiation of antineoplastic therapy to allow time for the vaccine to start acting?

1 Answer available

How do you counsel patients with newly diagnosed transplant-ineligible multiple myeloma on the expectations of treatment in terms of disease control, duration of therapy, monitoring and follow up?

3 Answers available

What level of 24h urine M protein do you consider to define active myeloma in a patient with renal insufficiency, proteinuria and monoclonal gammopathy?

When do you start treatment in this case?

1 Answer available

What would be your preferred second line treatment for a frail elderly patient progressing on Rd?

1 Answer available

How do you determine when to use a maintenance regimen vs continuous 3-drug regimen in a transplant-ineligible MM patient after response to first line therapy?

How is this impacted by patient features, cytogenetics/disease biology, depth of response, or other factors? What would compel you to continue 3 drugs...

3 Answers available

What clinical factors impact your upfront treatment decisions in transplant-ineligible MM?

How do you factor in patient age, frailty, patients with underlying organ dysfunction, or other clinical features? Do you still consider CyBorD or R...

3 Answers available

When, if ever, would you choose a two-drug regimen instead of three drug regimen first line in patients with transplant-ineligible Myeloma?

4 Answers available

What factors besides disease progression would lead you to de-intensify or change MM therapy for a patient with ongoing response?

In your experience, do certain regimens have more cumulative toxicity, financial impact, or patient convenience factors?

3 Answers available

When do you consider re-treatment with lenalidomide in later line therapy for relapsed multiple myeloma?

Are there scenarios where you would use a higher dose of lenalidomide in a novel doublet or triplet (eg. relapse on lenalidomide maintenance)?

1 Answer available

How would you manage multiple myeloma with a suboptimal response to frontline quadruplet therapy?

When would you consider utilizing autologous SCT in those with a PR or SD? Is there a potential role for BCMA-directed CAR-T or bispecific therapy in...

1 Answer available

What is your approach to the treatment of gamma heavy chain disease (Franklin's disease)?

How do you distinguish this entity from other plasma cell disorders (eg. MGUS, MM, etc.)? Review of literature suggests that most of these pa...

1 Answer available

How do you use daratumumab in the treatment of systemic AL amyloidosis?

What regimens would you consider combining it with? Any specific combinations to avoid or special considerations?

1 Answer available

What would be the ideal patient to receive selinexor-based therapy over other options for penta-refractory multiple myeloma?

Excluding clinical trials

1 Answer available

How do you risk stratify complex karyotype in newly diagnosed multiple myeloma in the absence of specific high-risk cytogenetic abnormalities?

2 Answers available

Why are autoantibodies not often detected on monoclonal gammopathy assays (SPEP/IFE, quantitiative immunoglobulins)?

For example, in cold agglutinin disease or AIHA, antibodies can be detected via DAT, but are often not observed on assays for monoclonal gammopathies.

1 Answer available

How would you treat non-secretory myeloma in an inpatient setting?

Does your management change based on the type of end-organ involvement at the time of diagnosis? Are there any reports of CNS involvement with non-se...

2 Answers available

Is there any benefit in continuing VRd instead of VR as maintenance therapy in transplant ineligible multiple myeloma?

2 Answers available

For patients with cancer receiving a bone-modifying agent (bisphosphonate or denosumab) who suffer a fracture requiring stabilization or reconstruction, how do you manage the bone-modifying agent peri-operatively?

Is there concern for impaired healing? Do you pause therapy and for how long?

1 Answer available

Is there a role for MRD monitoring in the decision to switch from a triplet regimen to maintenance therapy in transplant-ineligible myeloma patients?

1 Answer available

How do you approach treatment in a patient with a solitary plasmacytoma with minimal marrow involvement (< 10% clonal plasma cells)?

Is there any data justifying the use of systemic therapy over localized therapy (e.g. radiation or surgery) in this situation prior to a progression e...

2 Answers available

Under what circumstances do you consider double autologous stem cell transplants for patients with multiple myeloma?

4 Answers available

How do you treat newly diagnosed multiple myeloma with 1q gain?

Given the recent reclassification of gain(1q21) as a high risk cytogenetic abnormality, has this changed your practice in managing newly diagnosed pat...

1 Answer available

In a patient with multiple myeloma who cannot tolerate lenalidomide or bortezomib due to GI toxicity, what regimen would you choose for next-line therapy?

Is there evidence for daratumumab-based doublet regimens? Would your choice differ based on the patient's transplant eligibility?

1 Answer available

Do you hold maintenance lenalidomide or bortezomib for a patient who needs a surgery?

For example, for joing replacement surgery? Do you hold the revlimid for certain about of time before and after?

1 Answer available

How do you manage severe lenalidomide-associated drug rash in a transplant-eligible patient with multiple myeloma?

Would your approach change based on the type of reaction (eg. Stevens-Johnson syndrome vs DRESS)? How would you address maintenance (if any) post-tra...

1 Answer available

Is there any role for bisphosphonate or alternative bone-modifying agents use in SMM in the absence of other indications for its use?

1 Answer available

Is there any role for early stem cell mobilization and collection during the SMM phase?

Do you worry about the ability to collect stem cells (at the time of progression to MM) if someone with SMM has been on prolonged lenalidomide?

1 Answer available

How long do you treat with IMID in a case of smoldering multiple myeloma?

1 Answer available

Does high risk cytogenetics as a sole abnormality influence your treatment decision for smoldering multiple myeloma?

1 Answer available

How do you treat anaplastic multiple myeloma?

What features are used to distinguish anaplastic multiple myeloma (AMM), and what other conditions should be considered in a differential diagnosis (e...

1 Answer available

Would you consider using daratumumab in the first line setting for non-transplant eligible multiple myeloma?

To me, the recent NEJM study is flawed in that the control arm did not have maintenance treatment while the experimental arm used maintenance Dar...

5 Answers available

How would you manage a patient with a solitary plasmacytoma with a partial response to RT?

Would you recommend surgical resection if feasible? Or just monitor every 3-6 months as NCCN guidelines suggest? Would your management differ based o...

2 Answers available

What is your approach to a patient with systemic AL amyloidosis who has achieved a hematologic response but not an organ response with CyBorD?

Would you proceed to autologous transplant, or switch to an alternate regimen (eg. daratumumab-based) first? Would the type or degree of organ involv...

1 Answer available

How do you approach a patient with IgM monoclonal gammopathy associated with severe neuropathy of unclear etiology?

2 Answers available

Do you perform biomarker-based screening for AL amyloidosis in patients with newly diagnosed MGUS?

If so, what is your approach to laboratory and clinical testing?

1 Answer available

How do you approach the workup and initial treatment of systemic AL amyloidosis?

Once a tissue biopsy has confirmed light chain amyloid, what additional tests do you perform as part of a standard workup? In whom should treatment b...

1 Answer available

How would you decide on VRd vs DRd for initial management of transplant ineligible multiple myeloma?

Are there specific patient groups where you would choose one over the other? Are the cost differences significant enough to dissuade you from choosin...

1 Answer available

How do you manage patients who develop de novo or recurrent skin cancers (SCC or BCC) while on lenalidomide?

Do these events mandate discontinuation of lenalidomide therapy or switching to a different agent? Can appropriate therapy for these skin cancers be r...

1 Answer available

Do you recommend lenalidomide for high risk smoldering multiple myeloma?

Given the PFS benefit seen in the most recent ECOG-ACRIN, and the prior study of Rd showing an OS benefit, is your practice to put any high-risk SMM p...

1 Answer available

What dosing regimen of carfilzomib do you use in the front line setting for high risk transplant-eligible multiple myeloma?

3 Answers available

In a patient with Waldenstrom's macroglobulinemia doing well and feeling better on ibrutinib & rituximab, but with a rising IgM, do you switch treatment or continue?

1 Answer available

What is your preferred maintenance therapy in young, fit patients with de novo plasma cell leukemia who achieve complete response after autologous stem cell transplantation?

2 Answers available

How do you treat a gastric plasmacytoma which is not amenable to radiation?

1 Answer available

When do you offer consolidative tandem autologous stem cell transplantation for high-risk multiple myeloma?

For example - Would you offer tandem transplantation in a young, fit patient in a CR after first transplant, but with MRD detectable?

1 Answer available

Can post op RT be omitted in a surgically repaired pathological fracture site in multiple myeloma if the patient will receive systemic therapy?

1 Answer available

With recent measles outbreaks occurring in the US, would you consider offering multiple myeloma patients s/p ASCT on maintenance treatment vaccination, or an alternate means of immunity?

Although the MMR vaccine is contraindicated in immunosuppressed patients on anticancer treatment according to CDC/ACIP and IDSA guidelines, data on sa...

1 Answer available

Would detection of an adverse cytogenetic marker such as dup(1q) alone in the setting of MGUS satisfy criteria for a diagnosis of multiple myeloma?

1 Answer available

In transplant-eligible, fit patients with multiple myeloma who have an inadequate response to front-line therapy, what regimen would you choose for second-line?

Given the recent results presented from the Griffin trial, would you choose a daratumumab-based regimen (eg. D-VRd) over other salvage options (V...

1 Answer available

What is your preferred first-line therapy for a patient with standard risk multiple myeloma?

Has the recent data presented at ASH affected your choice of regimen? Would your choice differ between transplant-eligible and transplant-ineligible ...

1 Answer available

Is there a role for assessing measurable/minimal residual disease (MRD) in multiple myeloma at this time?

Would MRD assessments affect your clinical decision making for MM patients outside of a clinical trial?

1 Answer available

When do you choose to give CyBorD over RVd in a newly diagnosed myeloma patient?

Specifically, what regimen would you choose in a patient with new renal failure but not requiring dialysis?

3 Answers available

How do you utilize lenalidomide maintenance in non-transplant eligible myeloma?

Does the choice of initial induction regimen affect your decision for when to employ lenalidomide maintenance? Are there situations where you would c...

1 Answer available

What is your preferred approach to therapy in transplant ineligible multiple myeloma initially treated with CyBorD owing to acute renal failure, after achieving a VGPR (+IFE alone) with continued mild-moderate renal impairment?

Would you change to an alternative triplet therapy, or switch to maintenance therapy? Are there variations in depth of response short of CR that woul...

1 Answer available

What are some preferred steroid sparing regimens for untreated multiple myeloma patients who have type 1 diabetes mellitus?

1 Answer available

What is your preferred approach to the treatment of transplant ineligible multiple myeloma that has been treated with a triplet regimen and reached a plateau phase?

Would you observe until progression or would you place the patient on maintenance?

1 Answer available

How would you approach a patient with smoldering myeloma that has a quickly rising and very high M-spike (6 g/dL range)?

Once you decide to begin treatment, any special precautions you would use for protein levels starting that high.

1 Answer available

Do you ever consider the use of weekly (as opposed to bi-weekly bortezomib) for newly diagnosed multiple myeloma patients who are transplant eligible?

1 Answer available

When treating a patient with multiple myeloma with bortezomib, how do you decide between subcutaneous vs intravenous dosing?

Subq has been shown to have lower risk of neuropathy. Is there any reason to use weekly IV still?

3 Answers available

How would you treat a fit, newly diagnosed, high-risk multiple myeloma patient with multiple poor risk factors and circulating plasma cells?

In a patient with multiple poor risk features including TP53 mutation, 1q amplification, stage III, and circulating plasma cells, would you consider a...

1 Answer available

When do you consider re-starting treatment for a patient with relapsed myeloma?

For example, how significant does the M protein have to increase for you to begin a conversation about new therapy?

2 Answers available

How do you choose among regimens for relapsed refractory myeloma?

Specifically, to you lean towards elotuzumab or a daratumumab-based regimen?

1 Answer available

Given the sensitivity and prognostic value of the serum free light chain ratio for light chain multiple myeloma, do you continue to check urine studies?

2 Answers available

In multiple myeloma patients on bortezomib and dexamethasone, who develop HZV reactivation while on HZV prophylaxis, do you stop bortezomib/dexamethasone permanently?

1 Answer available

If a patient with myeloma develops a symptomatic DVT or PE while on an immunomodulatory drug such as lenalidomide, would you stop the IMiD?

Would you ever give another IMiD?

2 Answers available

How do you manage the development of neuropathy in patients receiving bortezomib for multiple myeloma?

At what point is the neuropathy a contraindication to further bortezomib therapy?

1 Answer available

Has the combination of daratumumab, bortezomib, and dexamethasone been tried for the treatment of plasma cell leukemia?

1 Answer available

Papers discussed in this category

JAMA, 2013-04-03

Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.

Haematologica, 2016-12-01

Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial.

Clin Pharmacokinet, 2012-12-01

Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma.

Blood, 2016-12-22

Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma.

The New England journal of medicine, 2015-08-13

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.

The Lancet. Oncology, 2010-01

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.

The New England journal of medicine, 2014-09-04

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.

The New England journal of medicine, 2019-05-30

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.

Lancet (London, England), 2017-02-04

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.

The New England journal of medicine, 2018-02-08

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.

Blood, 2018-01-18

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma.

N Engl J Med,

Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993-05

Primary systemic amyloidosis: a rare complication of immunoglobulin M monoclonal gammopathies and Waldenström's macroglobulinemia.

British journal of haematology, 2018-10

Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells.

Blood Adv,

Multicenter phase 2 study of daratumumab monotherapy in patients with previously treated Waldenström macroglobulinemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-10-10

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.

The New England journal of medicine, 2017-04-06

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

Haematologica, 2011 Nov 04

Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease.

Clin. Cancer Res., 2011 Feb 16

The progression from MGUS to smoldering myeloma and eventually to multiple myeloma involves a clonal expansion of genetically abnormal plasma cells.

J. Clin. Oncol., 2013 Oct 21

Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.

Bone marrow transplantation, 2018-07

Safety of live-attenuated measles-mumps-rubella and herpes zoster vaccination in multiple myeloma patients on maintenance lenalidomide or bortezomib after autologous hematopoietic cell transplantation.

Blood, 2016 Mar 21

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial.

Lancet Oncol, 2020 Aug 28

Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.

N. Engl. J. Med.,

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.

Leukemia, 2014-03

Consolidation and maintenance therapy with lenalidomide, bortezomib and dexamethasone (RVD) in high-risk myeloma patients.

The Lancet. Oncology, 2014-03

Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.

The New England journal of medicine, 2012-05-10

Lenalidomide after stem-cell transplantation for multiple myeloma.

Leukemia, 2019-01

Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma.

BMC Cancer, 2006 May 05

Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study.

International journal of radiation oncology, biology, physics, 2001-05-01

Solitary plasmacytoma treated with radiotherapy: impact of tumor size on outcome.

International journal of radiation oncology, biology, physics, 1998-07-15

Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy.

Blood cancer journal, 2018-06-12

Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.

Leukemia, 2013-08

Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma.

J. Clin. Oncol., 2019 Oct 25

Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma.

Clinical lymphoma, myeloma & leukemia, 2016-09

Anaplastic Multiple Myeloma: An Aggressive Variant With a Poor Response to Novel Therapies.

Leuk. Lymphoma, 2011 Feb 08

Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study.

Cancer,

A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma.

Leukemia, 2009-10

International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).

Ann. Allergy Asthma Immunol., 2019 Aug 07

A practical 16-day desensitization protocol in lenalidomide-induced non-immediate hypersensitivity reactions.

Clin Lymphoma Myeloma Leuk,

Practical Management of Lenalidomide-Related Rash.

Blood, 2012-01-05

The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis.

Lancet (London, England), 2019-01-19

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.

The Lancet. Oncology, 2019-01

Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.

Lancet Haematol, 2020 Apr 30

Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.

Leukemia, 2017 Jul 04

Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial.

Clin Lymphoma Myeloma Leuk, 2020 Mar 06

Heavy Lifting: Nomenclature and Novel Therapy for Gamma Heavy Chain Disease and Other Heavy Chain Disorders.

J Hematol Oncol, 2018 Jan 16

Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel.

Blood, 2017-07-06

Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma.

The Lancet. Oncology, 2019-06

International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders.

Lancet, 2019 Jun 03

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.

Blood,

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.

Leuk Lymphoma, 2011 Dec 13

Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial.

Haematologica, 2019 Oct 03

Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial.

Ann Hematol, 2020 Apr 19

Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myeloma.

Lancet Oncol, 2019 Dec 16

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.

N Engl J Med,

Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.

Lancet,

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.

Blood, 2007-01-15

Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial.

Blood,

A prospective phase 2 trial of daratumumab in patients with previously treated systemic light-chain amyloidosis.

Blood, 2017 Jan 27

A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis.

Blood, 2013-10-24

The impact of response on bone-directed therapy in patients with multiple myeloma.

The Lancet. Oncology, 2011-08

Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial.

The Lancet. Oncology, 2018-03

Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.

Leukemia, 2018 Apr 25

Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN).

Blood Cancer J, 2021 May 12

A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab.

Leuk Lymphoma, 2019 Nov 18

Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma.

Blood, 2013-10-03

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.

Leukemia, 2019-09

Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.

J Clin Oncol, 2012 Jul 16

Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

Lancet (London, England), 2016-04-09

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.

The Lancet. Oncology, 2019-06

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.

Lancet Oncol,

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.

Strahlenther Onkol, 2017 Jun 01

Single vs. multiple fraction regimens for palliative radiotherapy treatment of multiple myeloma : A prospective randomised study.

Nature communications, 2019-04-23

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis.

Blood, 2012 Aug 13

Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial.

J Clin Oncol, 2020 Apr 16

Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma.

Blood,

Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma.

Blood,

Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.

N Engl J Med,

Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.

The New England journal of medicine, 2018-11-08

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.

Eur J Haematol, 2021 Aug 11

Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple-class relapsed/refractory multiple myeloma (RRMM).

Lancet Oncol, 2020 Oct 29

Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial.

Blood Adv, 2021 Sep 01

Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.

Cell,

Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy.

Am J Hematol, 2021 Jul 05

Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials.

The Lancet. Oncology, 2018-07

Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.

Blood Cancer J, 2020 Mar 09

Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis.

JAMA Oncol,

Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial.

JAMA, 2016-11-15

Clinical Practice Guidelines From the AABB: Red Blood Cell Transfusion Thresholds and Storage.

N Engl J Med,

A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group.

J Clin Oncol, 2019 Apr 10

Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update.

J Clin Oncol, 2020 Feb 21

Liberal Versus Restrictive Red Blood Cell Transfusion Thresholds in Hematopoietic Cell Transplantation: A Randomized, Open Label, Phase III, Noninferiority Trial.

J Clin Oncol, 2020 Oct 06

Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial.

The Lancet. Oncology, 2021 Oct 13

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.

The Lancet. Haematology, 2023 Sep 11

Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.

JCO Oncol Pract, 2020 Aug 21

Changes in Intravenous Immunoglobulin Usage for Hypogammaglobulinemia After Implementation of a Stewardship Program.

Mayo Clin Proc,

Monoclonal Gammopathy-Associated Peripheral Neuropathy: Diagnosis and Management.

Neurol Sci, 2021 Sep 16

Paraproteinemia and neuropathy.

Journal of clinical pathology, 2017-09

Plasmablastic lymphoma versus plasmablastic myeloma: an ongoing diagnostic dilemma.

Leukemia, 2018-06

Treatment approaches and outcomes in plasmacytomas: analysis using a national dataset.

American journal of kidney diseases : the official journal of the National Kidney Foundation, 2017-05

Acute Kidney Allograft Rejection Precipitated by Lenalidomide Treatment for Multiple Myeloma.

Transplant Proc,

Severe Renal Allograft Rejection Resulting from Lenalidomide Therapy for Multiple Myeloma: Case Report.

Clin Lymphoma Myeloma Leuk, 2020 Mar 07

Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With Selinexor.

Clin Lymphoma Myeloma Leuk, 2021 Jul 18

Optimal Supportive Care With Selinexor Improves Outcomes in Patients With Relapsed/Refractory Multiple Myeloma.

Blood Cancer J, 2021 Jan 11

Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis.

JAMA Oncol,

Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial.

Blood Cancer J, 2020 May 11

Venetoclax for the treatment of translocation (11;14) AL amyloidosis.

Lancet Oncol, 2019 Oct 23

Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial.

Blood, 2011-09-15

Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease.

Haematologica, 2011 Dec 01

Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial.

Cancer Chemother Pharmacol, 2016 Jun 10

Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment.

Clin Cancer Res, 2020 Aug 17

Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation.

American journal of hematology, 2019-11

Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score.

J Clin Oncol, 2011 Jan 31

Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.

J Natl Compr Canc Netw,

Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug-Associated Thrombosis Among Patients With Multiple Myeloma.

J Clin Oncol, 2021 Aug 13

Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14).

Blood, 2015-03-26

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report.

Clin Lymphoma Myeloma Leuk, 2019 Oct 09

Adherence to Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma.

JCO Oncol Pract, 2019 Nov 25

Integrating Touchscreen-Based Geriatric Assessment and Frailty Screening for Adults With Multiple Myeloma to Drive Personalized Treatment Decisions.

Lancet Haematol,

The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.

Leukemia, 2020 Jul 21

Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE.

Clin Lymphoma Myeloma Leuk, 2020 Jul 29

Modified Hyper-CVAD With Proteasome Inhibition for Multiple Myeloma: A Single-Center Retrospective Analysis.

Lancet Oncol, 2014 Oct 26

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

Blood cancer journal, 2016-07-29

Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma.

Leukemia, 2022 Apr 11

Correction: Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100.

N Engl J Med, 2022 Jun 05

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.

N Engl J Med,

Monoclonal Gammopathy of Renal Significance.

American journal of hematology, 2019-05

Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma.

Amyloid, 2017 Apr 23

Amyloid in bone marrow smears in systemic light-chain amyloidosis.

Leukemia, 2015 Oct 07

Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma.

British journal of haematology, 2017-10

Natural history of amyloidosis isolated to fat and bone marrow aspirate.

Blood Adv,

Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone.

Blood Cancer J, 2018 May 24

Evaluation of minimal residual disease using next-generation flow cytometry in patients with AL amyloidosis.

Amyloid, 2019 Jan 20

Efficacy of lenalidomide as salvage therapy for patients with AL amyloidosis.

J Clin Oncol, 2022 Aug 12

Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial.

Proc Natl Acad Sci U S A, 2019 Apr 15

Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma.

N Engl J Med,

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.

Blood Cancer J, 2022 Sep 14

Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study.

Blood, 2018-01-11

How I manage monoclonal gammopathy of undetermined significance.

Blood,

Redefining nonmeasurable multiple myeloma using mass spectrometry.

N Engl J Med,

GPRC5D-Targeted CAR T Cells for Myeloma.

Clin Cancer Res, 2022 May 02

FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma.

Lancet, 2021 Jun 24

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.

Blood, 2022 Jan 27

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE.

Br J Haematol, 2021 Aug 15

Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis.

Blood, 2022 Dec 08

Abnormal metaphase cytogenetics predicts venous thromboembolism in myeloma: derivation and validation of the PRISM score.

Transpl Infect Dis, 2015 Sep 26

Incidence of infection according to intravenous immunoglobulin use in autologous hematopoietic stem cell transplant recipients with multiple myeloma.

Clin Lymphoma Myeloma Leuk, 2021 Feb 07

Efficacy of Intravenous Immunoglobulin for Preventing Infections in Patients with Multiple Myeloma.

Lancet, 1994 Apr 30

Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma.

N Engl J Med, 2022 Jun 05

Teclistamab in Relapsed or Refractory Multiple Myeloma.

J Clin Oncol, 2022 Jun 04

Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up.

J Clin Oncol, 2022 Oct 21

Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Relapsed/Refractory Multiple Myeloma (CARTIFAN-1).

Leukemia, 2019-03

Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse.

Journal of the American Society of Nephrology : JASN, 2007-03

Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies.

Lancet Haematol, 2019 Mar 11

High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial.

Blood Cancer J, 2022 Sep 02

Comparison of two free light chain assays: performance of the involved free light chain ratio and implications for diagnosis of multiple myeloma.

Cancer, 2021 Jun 28

Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma: The EMN09 phase 1/2 study of the European Myeloma Network.

Leukemia, 2022 Feb 21

Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100.

Lancet Haematol, 2019 Jul 18

Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial.

Lancet Haematol, 2019 Jul 18

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.

Br J Haematol, 2021 Jun 10

Pembrolizumab combined with carfilzomib and low-dose dexamethasone for relapsed or refractory multiple myeloma: Cohort 2 of the phase I KEYNOTE-023 study.

N Engl J Med, 2023 Jun 05

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.

N Engl J Med, 2023 Feb 10

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.

Lancet Oncol, 2021 Dec 03

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.

Lancet, 2021 Jun 04

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.

Blood, 2022 Oct 20

Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms.

Lancet Oncol, 2021 Nov 11

Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.

N Engl J Med, 2023 Jun 05

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma.

Br J Haematol, 2023 Jun 07

Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma.

J Clin Oncol, 2022 May 23

Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project.

Blood Cancer J, 2022 Jan 31

A simple additive staging system for newly diagnosed multiple myeloma.

Experimental hematology & oncology, 2022 Feb 28

Successful administration of chimeric antigen receptor (CAR) T-cell therapy in patients requiring hemodialysis.

Blood advances, 2020 Dec 08

A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021 Dec 13

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022 Apr 04

Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk.

The Lancet. Haematology, 2023 Sep 27

Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 Sep 27

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma.

American journal of hematology, 2022 Jul 05

Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25-year longitudinal study.

Blood advances, 2023 Oct 24

Predictors of treatment response and survival outcomes in patients with advanced cardiac AL amyloidosis.

Blood, 2018 Aug 14

Treatment of AL amyloidosis with bendamustine: a study of 122 patients.

Leukemia, 2024 Apr 09

Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures.

Haematologica, 2013-01

Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience.

The Lancet. Haematology, 2015 May 06

Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational study.

European respiratory review : an official journal of the European Respiratory Society, 2017 Sep 06

The lung in amyloidosis.

Mayo Clinic proceedings, 2017-06

Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: The Mayo Clinic Experience.

Blood advances, 2017 Dec 21

Bone disease in monoclonal gammopathy of undetermined significance: results from a screened population-based study.

British journal of clinical pharmacology, 2010 May

Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy.

Blood, 2023 Nov 30

Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas.

Cancer, 2011-10-01

Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy.

International journal of radiation oncology, biology, physics, 2006-01-01

Outcomes and patterns of failure in solitary plasmacytoma: a multicenter Rare Cancer Network study of 258 patients.

Blood, 2014 May 29

Multiparameter flow cytometry for staging of solitary bone plasmacytoma: new criteria for risk of progression to myeloma.

Blood, 2014 Jun 17

Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis.

International journal of radiation oncology, biology, physics, 2011 Jan 27

Multi-institutional analysis of solitary extramedullary plasmacytoma of the head and neck treated with curative radiotherapy.

Leukemia & lymphoma, 2021 Feb 03

Bloodless chimeric antigen receptor (CAR) T-cell therapy in Jehovah's Witnesses.

Dominion law reports, 1990 Mar 30

Malette v. Shulman.

Transplantation and cellular therapy, 2022 Dec 06

Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials.

American journal of hematology, 2019-04

Progression with clinical features is associated with worse subsequent survival in multiple myeloma.

Blood advances, 2023 Mar 28

Outcomes after biochemical or clinical progression in patients with multiple myeloma.

American journal of hematology, 2023 Jul 08

Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma.

Blood cancer journal, 2024 Apr 15

In multiple myeloma, monthly treatment with zoledronic acid beyond two years offers sustained protection against progressive bone disease.

Blood cancer journal, 2019 Nov 25

Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone.

British journal of haematology, 2019 Dec 09

Daratumumab in high-risk relapsed/refractory multiple myeloma patients: adverse effect of chromosome 1q21 gain/amplification and GEP70 status on outcome.

The New England journal of medicine, 2023 Dec 12

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Blood cancer journal, 2024 Apr 22

Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015-05

Management of relapsed multiple myeloma after autologous stem cell transplant.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012-03-20

Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.

Blood, 2010-12-09

Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features.

Clinical chemistry, 2005-05

Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice.

Clinical chemistry and laboratory medicine, 2016 Jun 01

A patient with AL amyloidosis with negative free light chain results.

ESC heart failure, 2021 May 07

Advanced isolated light chain amyloid cardiomyopathy with negative immunofixation and normal free light chain ratio.

Lancet (London, England), 2019 Dec 10

Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.

The New England journal of medicine, 2024 Jun 03

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Nature medicine, 2024 Jun 03

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial.

Blood, 2023 Jan 19

Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents.

The New England journal of medicine, 2024 Jun 01

Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma.

The New England journal of medicine, 2024 Jun 02

Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma.

Clinical pharmacokinetics, 2017 Feb

Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide.

Cancer chemotherapy and pharmacology, 2016 Dec 30

Population pharmacokinetics of lenalidomide in multiple myeloma patients.

Blood cancer journal, 2018-11-19

Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022 Jun 06

High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022 Oct 31

More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022 Jun 06

Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma.

Transplant Cell Ther, 2023 Mar 17

Safety and Efficacy of BCMA CAR-T Cell Therapy in Older Patients With Multiple Myeloma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 Oct 24

Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy.

Blood advances, 2023 Aug 22

Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma.

Kidney international, 2018-07

Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits is associated with high rate of early recurrence in the allograft.

BMC nephrology, 2019-02-14

Complete biopsy-proven resolution of deposits in recurrent proliferative glomerulonephritis with monoclonal IgG deposits (PGNMIGD) following rituximab treatment in renal allograft.

Leukemia & lymphoma, 2024 Apr 16

Prevalence of geriatric impairments and frailty categorization among real-world patients with multiple myeloma: a prospective cohort study (MFRAIL).

International journal of radiation oncology, biology, physics, 2024 Oct 27

Irradiated Bone Marrow Volume is Associated with Hematologic Toxicity in Patients with Multiple Myeloma.

The Lancet. Oncology, 2022 Feb 10

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.

Blood cancer journal, 2023 May 09

Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.

Platelets, 2023 Oct 11

Multiple myeloma and its treatment contribute to increased platelet reactivity.

Blood, 2011 Aug 11

Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.

Blood, 2024 Aug 08

Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study.

Nature medicine, 2023 Aug 15

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.

The New England journal of medicine, 2024 Dec 09

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.

Blood cancer journal, 2020 Oct 16

International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM).

Blood advances, 2023 Nov 14

CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies.

Myeloma

Questions discussed in this category

Papers discussed in this category

Related Topics